Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy
Gespeichert in:
| Veröffentlicht in: | Cancer 2002-11, Vol.95 (9), p.2038-2039 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2039 |
|---|---|
| container_issue | 9 |
| container_start_page | 2038 |
| container_title | Cancer |
| container_volume | 95 |
| creator | Akçali, Zafer Akin, Ebru Özyilkan, Özgür |
| description | |
| doi_str_mv | 10.1002/cncr.10896 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72619092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72619092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2356-f468f374fefc231234fbdae8ee067e68d7f53a8603ff98a6959268c9c71452143</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EokvhwgMgnzigptiO8--IVi0gVa1UgcQtcpwxMXLsMHZa9sYj8Fa8B0-Ct7sSN04z4_n0aawfIS85O-eMibfaa8xd29WPyIazrikYl-Ix2TDG2qKS5ZcT8izGb3lsRFU-JSdcSCZLxjbk96XSKWCkC8JodbL-K0WIS_ARqPIjjSve2TvlqPWUy44uKlnwKdJ7mya6-gyDTmpwQCfIy6DBudUppFqhtj7MiiYElWCkw47qMA_WZ0fwVNu4uNz6syxPgAYw-D8_fym3TOqMjuFHwHWwWfJwSZVXxq0Bw4pKW0f1BHNIE6Bads_JE6NchBfHeko-X1582n4orm7ef9y-uyq0KKu6MLJuTdlIAyY_cFFKM4wKWgBWN1C3Y2OqUrU1K43pWlV3VSfqVne64bISXJan5PXBu2D4vkJM_Wzj_svKQ1hj34iad6wTGXxzADWGGBFMv6CdFe56zvp9bP0-tv4htgy_OlrXYYbxH3rMKQP8ANxbB7v_qPrt9fb2IP0Lc_OqtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72619092</pqid></control><display><type>article</type><title>Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Akçali, Zafer ; Akin, Ebru ; Özyilkan, Özgür</creator><creatorcontrib>Akçali, Zafer ; Akin, Ebru ; Özyilkan, Özgür</creatorcontrib><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.10896</identifier><identifier>PMID: 12404300</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Cisplatin - administration & dosage ; Doxorubicin - administration & dosage ; Fluorouracil - administration & dosage ; Humans ; Interferon-alpha - administration & dosage ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Recombinant Proteins ; Survival Rate</subject><ispartof>Cancer, 2002-11, Vol.95 (9), p.2038-2039</ispartof><rights>Copyright © 2002 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2356-f468f374fefc231234fbdae8ee067e68d7f53a8603ff98a6959268c9c71452143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.10896$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.10896$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12404300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akçali, Zafer</creatorcontrib><creatorcontrib>Akin, Ebru</creatorcontrib><creatorcontrib>Özyilkan, Özgür</creatorcontrib><title>Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy</title><title>Cancer</title><addtitle>Cancer</addtitle><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Cisplatin - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Recombinant Proteins</subject><subject>Survival Rate</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhy0EokvhwgMgnzigptiO8--IVi0gVa1UgcQtcpwxMXLsMHZa9sYj8Fa8B0-Ct7sSN04z4_n0aawfIS85O-eMibfaa8xd29WPyIazrikYl-Ix2TDG2qKS5ZcT8izGb3lsRFU-JSdcSCZLxjbk96XSKWCkC8JodbL-K0WIS_ARqPIjjSve2TvlqPWUy44uKlnwKdJ7mya6-gyDTmpwQCfIy6DBudUppFqhtj7MiiYElWCkw47qMA_WZ0fwVNu4uNz6syxPgAYw-D8_fym3TOqMjuFHwHWwWfJwSZVXxq0Bw4pKW0f1BHNIE6Bads_JE6NchBfHeko-X1582n4orm7ef9y-uyq0KKu6MLJuTdlIAyY_cFFKM4wKWgBWN1C3Y2OqUrU1K43pWlV3VSfqVne64bISXJan5PXBu2D4vkJM_Wzj_svKQ1hj34iad6wTGXxzADWGGBFMv6CdFe56zvp9bP0-tv4htgy_OlrXYYbxH3rMKQP8ANxbB7v_qPrt9fb2IP0Lc_OqtQ</recordid><startdate>20021101</startdate><enddate>20021101</enddate><creator>Akçali, Zafer</creator><creator>Akin, Ebru</creator><creator>Özyilkan, Özgür</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021101</creationdate><title>Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy</title><author>Akçali, Zafer ; Akin, Ebru ; Özyilkan, Özgür</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2356-f468f374fefc231234fbdae8ee067e68d7f53a8603ff98a6959268c9c71452143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Cisplatin - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Recombinant Proteins</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akçali, Zafer</creatorcontrib><creatorcontrib>Akin, Ebru</creatorcontrib><creatorcontrib>Özyilkan, Özgür</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akçali, Zafer</au><au>Akin, Ebru</au><au>Özyilkan, Özgür</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2002-11-01</date><risdate>2002</risdate><volume>95</volume><issue>9</issue><spage>2038</spage><epage>2039</epage><pages>2038-2039</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12404300</pmid><doi>10.1002/cncr.10896</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2002-11, Vol.95 (9), p.2038-2039 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72619092 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Cisplatin - administration & dosage Doxorubicin - administration & dosage Fluorouracil - administration & dosage Humans Interferon-alpha - administration & dosage Liver Neoplasms - drug therapy Liver Neoplasms - mortality Recombinant Proteins Survival Rate |
| title | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A26%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20predicting%20response%20and%20survival%20in%20149%20patients%20with%20unresectable%20hepatocellular%20carcinoma%20treated%20by%20combination%20cisplatin,%20interferon%E2%80%90alpha,%20doxorubicin%20and%205%E2%80%90fluorouracil%20chemotherapy&rft.jtitle=Cancer&rft.au=Ak%C3%A7ali,%20Zafer&rft.date=2002-11-01&rft.volume=95&rft.issue=9&rft.spage=2038&rft.epage=2039&rft.pages=2038-2039&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.10896&rft_dat=%3Cproquest_cross%3E72619092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72619092&rft_id=info:pmid/12404300&rfr_iscdi=true |